Related Experiment Video

Updated: Dec 25, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.6K

Prostate-specific membrane antigen PET-CT before radical treatment

Caroline Moore1

  • 1Urology Department, University College London, London WC1E 6BT, UK.

Lancet (London, England)
|March 27, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

558
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K

Related Experiment Videos

Last Updated: Dec 25, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.6K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

558
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

6.8K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.8K

Articles linked to this work by shared authors, journal, and citation graph.

Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.

European urology·2026

ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy.

European urology·2026

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.

JAMA oncology·2026

Transcriptional responses to chronic oxidative stress require cholinergic activation of G-protein-coupled receptor signaling.

eLife·2026

Fatty acids-based compounds as novel prophylaxis or treatment for oropharyngeal Neisseria gonorrhoeae: an in vitro study.

Emerging microbes & infections·2026

Oral mucosal scrapes capture cancer associated microRNA expression consistent with histopathology.

Scientific reports·2026

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

Lancet (London, England)·2026

Robotic-arm-assisted versus conventional total knee replacement (RACER-Knee): a pragmatic, multicentre, participant-masked and assessor-masked, superiority, randomised controlled trial.

Lancet (London, England)·2026

Risk of transmission of amyloid β pathology via transfused blood products.

Lancet (London, England)·2026

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.

Lancet (London, England)·2026

Expanding the phenotype of hereditary renal cell carcinoma syndromes: Implications for surveillance and management.

Journal of the National Cancer Institute·2026

Periductal myxoid stroma identifies ductal carcinoma in situ at risk of invasive recurrence.

Journal of the National Cancer Institute·2026

Mayo Clinic classification of presacral tumors: evolution of classifications and systematic review of pathologies.

BJS open·2026

Survival outcomes of expansile versus infiltrative subtype in primary mucinous ovarian carcinomas: A retrospective study in Thailand.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026

Long-term prospective assessment of quality of life and physical function in malignant lymphoma patients undergoing chemotherapy.

Medicine·2026

Risk factors for local recurrence and metastasis of eyelid sebaceous carcinoma after complete excision: A large cohort study in Japan.

Indian journal of ophthalmology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us